Viewing Study NCT00036218



Ignite Creation Date: 2024-05-05 @ 11:25 AM
Last Modification Date: 2024-10-26 @ 9:07 AM
Study NCT ID: NCT00036218
Status: COMPLETED
Last Update Posted: 2006-06-07
First Post: 2002-05-08

Brief Title: Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinsons Disease
Sponsor: Pfizer
Organization: Pfizer

Study Overview

Official Title: A Phase III Double-Blind Placebo-Controlled Randomized Study Comparing the Efficacy Safety and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinsons Disease
Status: COMPLETED
Status Verified Date: 2006-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary purpose of this study is to determine whether sumanirole is effective and safe in the treatment of the signs and symptoms of early Parkinsons disease
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None